Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.18 USD | +1.18% | +1.73% | -2.12% |
05-09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
05-08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Sales 2024 * | 60.29B 82.52B | Sales 2025 * | 62.64B 85.73B | Capitalization | 160B 219B |
---|---|---|---|---|---|
Net income 2024 * | 7.18B 9.83B | Net income 2025 * | 11.14B 15.25B | EV / Sales 2024 * | 3.62 x |
Net Debt 2024 * | 58.11B 79.54B | Net Debt 2025 * | 49.97B 68.39B | EV / Sales 2025 * | 3.35 x |
P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
13.9
x | Employees | 88,000 |
Yield 2024 * |
5.89% | Yield 2025 * |
5.99% | Free-Float | 59.01% |
Latest transcript on Pfizer, Inc.
1 day | -0.12% | ||
1 week | +1.73% | ||
Current month | +9.99% | ||
1 month | +5.23% | ||
3 months | +2.25% | ||
6 months | -5.05% | ||
Current year | -2.12% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.74% | 0 M€ | +11.39% | - | |
9.37% | 0 M€ | +6.39% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 28.18 | -0.32% | 46,614,152 |
24-05-08 | 28.27 | +1.80% | 39,087,790 |
24-05-07 | 27.77 | -1.38% | 65,606,379 |
24-05-06 | 28.16 | +1.26% | 59,899,707 |
24-05-03 | 27.81 | +0.40% | 60,568,852 |
Delayed Quote Nyse, May 09, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.12% | 160B | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- PFE Stock